نتائج البحث - "Caroline Robert"

1

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer

المصدر: Future Oncology. 16:4429-4438

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test

2

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

المساهمون: Intégrité du génome, ARN et cancer, Institut Curie [Paris]-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), University of Zurich, Robert, Caroline

المصدر: European journal of cancer (Oxford, England : 1990)
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 144, pp.182-191. ⟨10.1016/j.ejca.2020.11.010⟩

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, [SDV]Life Sciences [q-bio], Immune-checkpoint inhibitors, Pembrolizumab, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune-related adverse events, Monoclonal, 80 and over, 1306 Cancer Research, Melanoma, Humanized, Cancer, Aged, 80 and over, Clinical Trials as Topic, 10177 Dermatology Clinic, Middle Aged, Prognosis, Advanced melanoma, 3. Good health, Immunological, Oncology, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Toxicity, Public Health and Health Services, 2730 Oncology, Female, PD-1 inhibitors, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Oncology and Carcinogenesis, 610 Medicine & health, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Article, Antibodies, Vaccine Related, 03 medical and health sciences, Young Adult, Meta-Analysis as Topic, Internal medicine, medicine, Humans, In patient, Oncology & Carcinogenesis, Adverse effect, Pneumonitis, Aged, Immunomodulating drugs, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Clinical trial, 030104 developmental biology, Corticosteroid use, Immunization, business, Follow-Up Studies

وصف الملف: application/pdf; 868_Robert_C._et_al._Long-term_safety_of_pembrolizumab_monotherapy_and_relationship_with_clinical_outcome_EJC_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c081e1b4e51d5ab8b097204bced3e77dTest
https://escholarship.org/uc/item/275859csTest

3

المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development

المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
European Journal of Cancer, 67, 46-54. Pergamon

مصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma

وصف الملف: 663_Schadendorf D. et al._Health-related quality of life in the randomised KEYNOTE-002_EJC 2016.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0340a48931fc5ff52f9246c04eeed519Test
https://doi.org/10.1016/j.ejca.2016.07.018Test

4

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006 : A randomised clinical trial

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379a23f5eaed8008bb5457e825ae223bTest
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85051002457Test

5

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

المصدر: The Lancet. 384:1109-1117

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::567ff1bc306785d4655b459c1c335c52Test
https://doi.org/10.1016/s0140-6736Test(14)60958-2

6

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

المساهمون: Laboratory of Molecullar and Cellular Therapy, Laboratory for Medical and Molecular Oncology, Clinical sciences, Medical Oncology

المصدر: Lancet (London, England). 390(10105)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Skin Neoplasms, Adolescent, Population, Phases of clinical research, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Endocrine System Diseases, Drug Administration Schedule, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Antineoplastic Agents, Immunological, Internal medicine, Journal Article, Medicine, Humans, education, Melanoma, Aged, Aged, 80 and over, education.field_of_study, Performance status, business.industry, Hazard ratio, General Medicine, Middle Aged, Colitis, Surgery, Regimen, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Female, Chemical and Drug Induced Liver Injury, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0b1b2d09def6d265b755196bc36b1baTest
https://pubmed.ncbi.nlm.nih.gov/28822577Test

7

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

المساهمون: University of Zurich, Hamid, Omid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business

وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test

8

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

المصدر: JAMA Oncol

مصطلحات موضوعية: advanced melanoma, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Adolescent, Dacarbazine, Medizin, Phases of clinical research, Ipilimumab, Pembrolizumab, Placebo, BRAF, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 030212 general & internal medicine, Nivolumab, wild-type, Antineoplastic Agents, Alkylating, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Correction, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c9b0d0b1e4e0e7e07096a725b4e567Test
https://doi.org/10.1001/jamaoncol.2018.4514Test

9

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

المساهمون: University of Zurich, Ribas, Antoni

المصدر: The Lancet. Oncology, vol 16, iss 8
Lancet Oncol

مصطلحات موضوعية: Oncology, Male, Skin Neoplasms, Time Factors, Medizin, Drug Resistance, Pembrolizumab, Kaplan-Meier Estimate, chemistry.chemical_compound, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, Melanoma, Humanized, Cancer, Aged, 80 and over, education.field_of_study, Antibodies, Monoclonal, 10177 Dermatology Clinic, Middle Aged, Intention to Treat Analysis, Treatment Outcome, 6.1 Pharmaceuticals, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Dacarbazine, Population, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Ipilimumab, Antineoplastic Agents, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Article, Antibodies, Disease-Free Survival, Young Adult, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, education, Aged, Performance status, business.industry, Evaluation of treatments and therapeutic interventions, Interim analysis, medicine.disease, Carboplatin, Surgery, chemistry, Drug Resistance, Neoplasm, Neoplasm, business, Progressive disease

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4cfc7c0dc19ed0d5bc8a82c2ccdcc1eTest
https://doi.org/10.5167/uzh-113041Test

10

Nivolumab in previously untreated melanoma without BRAF mutation

المصدر: Robert, C, Long, G V, Brady, B, Dutriaux, C, Maio, M, Mortier, L, Hassel, J C, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Savage, K J, Hernberg, M M, Lebbé, C, Charles, J, Mihalcioiu, C, Chiarion-Sileni, V, Mauch, C, Cognetti, F, Arance, A, Schmidt, H, Schadendorf, D, Gogas, H, Lundgren-Eriksson, L, Horak, C, Sharkey, B, Waxman, I M, Atkinson, V & Ascierto, P A 2015, ' Nivolumab in previously untreated melanoma without BRAF mutation ', The New England Journal of Medicine, vol. 372, no. 4, pp. 320-30 . https://doi.org/10.1056/NEJMoa1412082Test
New England Journal of Medicine; 372(4), pp 320-330 (2015)

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07253c758028e0b62a420832a391b6ecTest
https://pubmed.ncbi.nlm.nih.gov/25511188Test

تنقيح النتائج